Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, United Kingdom.
Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina, Greece.
JAMA. 2020 Feb 18;323(7):636-645. doi: 10.1001/jama.2019.22241.
The incremental value of polygenic risk scores in addition to well-established risk prediction models for coronary artery disease (CAD) is uncertain.
To examine whether a polygenic risk score for CAD improves risk prediction beyond pooled cohort equations.
DESIGN, SETTING, AND PARTICIPANTS: Observational study of UK Biobank participants enrolled from 2006 to 2010. A case-control sample of 15 947 prevalent CAD cases and equal number of age and sex frequency-matched controls was used to optimize the predictive performance of a polygenic risk score for CAD based on summary statistics from published genome-wide association studies. A separate cohort of 352 660 individuals (with follow-up to 2017) was used to evaluate the predictive accuracy of the polygenic risk score, pooled cohort equations, and both combined for incident CAD.
Polygenic risk score for CAD, pooled cohort equations, and both combined.
CAD (myocardial infarction and its related sequelae). Discrimination, calibration, and reclassification using a risk threshold of 7.5% were assessed.
In the cohort of 352 660 participants (mean age, 55.9 years; 205 297 women [58.2%]) used to evaluate the predictive accuracy of the examined models, there were 6272 incident CAD events over a median of 8 years of follow-up. CAD discrimination for polygenic risk score, pooled cohort equations, and both combined resulted in C statistics of 0.61 (95% CI, 0.60 to 0.62), 0.76 (95% CI, 0.75 to 0.77), and 0.78 (95% CI, 0.77 to 0.79), respectively. The change in C statistic between the latter 2 models was 0.02 (95% CI, 0.01 to 0.03). Calibration of the models showed overestimation of risk by pooled cohort equations, which was corrected after recalibration. Using a risk threshold of 7.5%, addition of the polygenic risk score to pooled cohort equations resulted in a net reclassification improvement of 4.4% (95% CI, 3.5% to 5.3%) for cases and -0.4% (95% CI, -0.5% to -0.4%) for noncases (overall net reclassification improvement, 4.0% [95% CI, 3.1% to 4.9%]).
The addition of a polygenic risk score for CAD to pooled cohort equations was associated with a statistically significant, yet modest, improvement in the predictive accuracy for incident CAD and improved risk stratification for only a small proportion of individuals. The use of genetic information over the pooled cohort equations model warrants further investigation before clinical implementation.
多基因风险评分在冠状动脉疾病(CAD)的既定风险预测模型之外的增量价值尚不确定。
研究 CAD 的多基因风险评分是否可以提高风险预测的效果,超过汇总队列方程。
设计、地点和参与者:英国生物库参与者的观察性研究,于 2006 年至 2010 年入组。使用 15947 例现患 CAD 病例和相等数量的年龄和性别频数匹配的对照,组成病例对照样本,基于已发表的全基因组关联研究的汇总统计数据,优化 CAD 的多基因风险评分的预测性能。使用 352660 名个体的单独队列(随访至 2017 年)评估 CAD 的多基因风险评分、汇总队列方程以及两者联合的预测准确性。
CAD 的多基因风险评分、汇总队列方程以及两者联合。
CAD(心肌梗死及其相关后果)。使用 7.5%的风险阈值评估了 CAD 的判别能力、校准和再分类。
在用于评估所检查模型的预测准确性的 352660 名参与者队列(平均年龄 55.9 岁,205297 名女性[58.2%])中,中位随访 8 年期间发生了 6272 例 CAD 事件。多基因风险评分、汇总队列方程和两者联合的 CAD 判别结果为 C 统计量分别为 0.61(95%CI,0.60 至 0.62)、0.76(95%CI,0.75 至 0.77)和 0.78(95%CI,0.77 至 0.79)。后两个模型之间 C 统计量的变化为 0.02(95%CI,0.01 至 0.03)。模型的校准显示出汇总队列方程的风险高估,经重新校准后得到了纠正。使用 7.5%的风险阈值,将多基因风险评分添加到汇总队列方程中,可使病例的净重新分类改善 4.4%(95%CI,3.5%至 5.3%),而非病例的净重新分类改善 0.4%(95%CI,-0.5%至-0.4%)(整体净重新分类改善 4.0%[95%CI,3.1%至 4.9%])。
CAD 的多基因风险评分与汇总队列方程联合使用,与 CAD 发病的预测准确性的统计学上显著但适度的提高相关,并仅使一小部分个体的风险分层得到改善。在临床实施之前,需要进一步研究遗传信息在汇总队列方程模型中的应用。